ALD

Neurology·MeSH: Sjogren's Syndrome

21 drugs in development·12 companies·1 clinical trial

Drug Pipeline by Phase

Approved(4)

Drug	Company
badger oil	Fuss Brands Corp. (FBDS)
caldolor	CUMBERLAND PHARMACEUTICALS INC (CPIX)
rayaldee	REPLIGEN CORP (RGEN)
spironolactone	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)

Phase 3(3)

Drug	Company
baxdrostat	ASTRAZENECA PLC (AZN)
Investigator's selection of appropriate chemotherapy regimen	Merus N.V. (MRUS)
Physician's choice chemotherapy	Merus N.V. (MRUS)

Phase 2(7)

Drug	Company
cin-107	CinCor Pharma, Inc. (CINC)
cin-107 2 mg dosing	ASTRAZENECA PLC (AZN)
cin-107 4 mg dosing	ASTRAZENECA PLC (AZN)
cin-107 8 mg dosing	ASTRAZENECA PLC (AZN)
iopofosine i 131 fractionated dose	Cellectar Biosciences, Inc. (CLRB)
iopofosine i 131 multiple dose	Cellectar Biosciences, Inc. (CLRB)
iopofosine i 131 single dose	Cellectar Biosciences, Inc. (CLRB)

Phase 1(3)

Drug	Company
apg2575	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
mb-106	MUSTANG BIO, INC. (MBIO)
VK0214	Viking Therapeutics, Inc. (VKTX)

Phase 4(4)

Drug	Company
Baxdrostat and dapagliflozin	ASTRAZENECA PLC (AZN)
Bortezomib	Filana Therapeutics Inc. (FLNA)
conventional chemotherapy	Merus N.V. (MRUS)
Thalidomide	Filana Therapeutics Inc. (FLNA)

BioSniper tracks 21 drugs in development for ALD across 12 companies.

There are 1 clinical trial targeting ALD tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.